Diagnostic, Prognostic and Theranostic Genetic Biomarkers forRheumatoid Arthritis

Cathy McGeough, AJ Bjourson

Research output: Contribution to journalArticle

Abstract

The identification and adoption of diagnostic and prognostic biomarkers for rheumatoid arthritis has informed and improved the clinical management of this disease. With the advent of biologic treatments such as anti-Tumour Necrosis Factor (anti-TNF) therapy, achieving disease remission has become a realistic endpoint for clinicians. The life-changing efficacy of these therapies however is restricted to the 60-70% of patients who respond. The immune reaction to anti-inflammatory therapy is thought to be influenced by many genes which cumulatively contribute to athreshold for response. There is an inherent clinical need to provide theranostic biomarkers which could determine treatment outcome. The current role of genetic biomarkers in diagnosis, prognosis and predicting response to anti-TNF therapy are discussed.
LanguageEnglish
JournalJournal of Clinical and Cellular Immunology
VolumeS6
DOIs
Publication statusPublished - 28 Jun 2012

Fingerprint

Arthritis
Biomarkers
Tumor Necrosis Factor-alpha
Therapeutics
Disease Management
Rheumatoid Arthritis
Anti-Inflammatory Agents
Theranostic Nanomedicine
Genes

Cite this

@article{71f617c79f58413b938b9213d5d932d2,
title = "Diagnostic, Prognostic and Theranostic Genetic Biomarkers forRheumatoid Arthritis",
abstract = "The identification and adoption of diagnostic and prognostic biomarkers for rheumatoid arthritis has informed and improved the clinical management of this disease. With the advent of biologic treatments such as anti-Tumour Necrosis Factor (anti-TNF) therapy, achieving disease remission has become a realistic endpoint for clinicians. The life-changing efficacy of these therapies however is restricted to the 60-70{\%} of patients who respond. The immune reaction to anti-inflammatory therapy is thought to be influenced by many genes which cumulatively contribute to athreshold for response. There is an inherent clinical need to provide theranostic biomarkers which could determine treatment outcome. The current role of genetic biomarkers in diagnosis, prognosis and predicting response to anti-TNF therapy are discussed.",
author = "Cathy McGeough and AJ Bjourson",
year = "2012",
month = "6",
day = "28",
doi = "10.4172/2155-9899.S6-002",
language = "English",
volume = "S6",

}

Diagnostic, Prognostic and Theranostic Genetic Biomarkers forRheumatoid Arthritis. / McGeough, Cathy; Bjourson, AJ.

Vol. S6, 28.06.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diagnostic, Prognostic and Theranostic Genetic Biomarkers forRheumatoid Arthritis

AU - McGeough, Cathy

AU - Bjourson, AJ

PY - 2012/6/28

Y1 - 2012/6/28

N2 - The identification and adoption of diagnostic and prognostic biomarkers for rheumatoid arthritis has informed and improved the clinical management of this disease. With the advent of biologic treatments such as anti-Tumour Necrosis Factor (anti-TNF) therapy, achieving disease remission has become a realistic endpoint for clinicians. The life-changing efficacy of these therapies however is restricted to the 60-70% of patients who respond. The immune reaction to anti-inflammatory therapy is thought to be influenced by many genes which cumulatively contribute to athreshold for response. There is an inherent clinical need to provide theranostic biomarkers which could determine treatment outcome. The current role of genetic biomarkers in diagnosis, prognosis and predicting response to anti-TNF therapy are discussed.

AB - The identification and adoption of diagnostic and prognostic biomarkers for rheumatoid arthritis has informed and improved the clinical management of this disease. With the advent of biologic treatments such as anti-Tumour Necrosis Factor (anti-TNF) therapy, achieving disease remission has become a realistic endpoint for clinicians. The life-changing efficacy of these therapies however is restricted to the 60-70% of patients who respond. The immune reaction to anti-inflammatory therapy is thought to be influenced by many genes which cumulatively contribute to athreshold for response. There is an inherent clinical need to provide theranostic biomarkers which could determine treatment outcome. The current role of genetic biomarkers in diagnosis, prognosis and predicting response to anti-TNF therapy are discussed.

U2 - 10.4172/2155-9899.S6-002

DO - 10.4172/2155-9899.S6-002

M3 - Article

VL - S6

ER -